đź’¨ Abstract
Larimar Therapeutics, Inc. reported a loss of $29.3 million and a loss of 46 cents per share in the first quarter of 2025, missing Wall Street expectations of a loss of 42 cents per share. This story was generated using data from Zacks Investment Research.
Courtesy: wtop.com
Summarized by Einstein Beta 🤖
Suggested
Meet David Corenswet, cinema’s new Superman -
Tariff turmoil prompts cloudy forecasts from companies for the year ahead -
First accuser resumes testimony at Harvey Weinstein’s #MeToo retrial -
Trump culpa a Biden por el mal desempeño de la economĂa mientras analistas destacan problemas causados por los aranceles -
Incendios forestales en las afueras de Jerusalén obligan a realizar evacuaciones y a cerrar carreteras -
Una fuente afirma que Ucrania y EE.UU. firmarĂan el esperado acuerdo sobre minerales este miĂ©rcoles -
Greece arrests an American citizen wanted by the U.S. in a child sexual exploitation case -
US-Audiobooks-Top-10 -
Giannis Antetokounmpo enters this offseason with a big question awaiting him. Stay or go? -
Nottingham Forest owner steps back from control of Premier League club -
Powered by MessengerX.io